About
Antibody-Oligonucleotide Conjugates
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapyAntibodySan Diego & Southern California
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
9
As Collaborator
1
Total Enrollment
1,384
By Phase
PHASE3: 3PHASE2: 3PHASE1/PHASE2: 3
By Status
ACTIVE_NOT_RECRUITING: 3COMPLETED: 3ENROLLING_BY_INVITATION: 2RECRUITING: 2
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT07008469Lead Sponsor
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
PHASE3Enrolling by invitation
217 participants
Started: Jul 25, 2025 · Completed: Oct 31, 2030
NCT07038200Lead Sponsor
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
PHASE3Recruiting
200 participants
Started: Jun 10, 2025 · Completed: Jul 31, 2028
NCT06547216Lead Sponsor
Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
PHASE2Enrolling by invitation
84 participants
Started: Jul 25, 2024 · Completed: Apr 30, 2028
NCT06411288Lead Sponsor
Global Study of Del-desiran for the Treatment of DM1
PHASE3Active, not recruiting
159 participants
Started: May 30, 2024 · Completed: Sep 30, 2026
NCT06244082Lead Sponsor
Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping
PHASE2Active, not recruiting
39 participants
Started: Jan 22, 2024 · Completed: Jul 31, 2027
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...